Vitamin B12

Clinical Summary

Cobalamin is a cobalt-centered corrinoid vitamin required for DNA synthesis (via methionine synthase → tetrahydrofolate regeneration) and mitochondrial succinyl-CoA production (via methylmalonyl-CoA mutase). Endogenous reserves in liver are 2–5 mg — enough for 3–5 years of depletion — which is why classic deficiency presents insidiously as macrocytic anemia or subacute combined degeneration (SACD).

The population most at risk: elderly (atrophic gastritis drops intrinsic factor), vegans (zero dietary intake), post-gastric-surgery patients, chronic metformin users (ADA 2026 now recommends annual B12 screening after 4 years metformin), PPI users (signal weaker than long claimed — PMID 40823471 MA null 2025), and recreational N₂O users (emerging public health signal — PMID 41396044).

The population where benefit is null or uncertain: cognitively and psychiatrically healthy adults with replete B12 status. The largest Mendelian randomization study to date (PMID 40739033) found null effect on 8 psychiatric disorders and cognitive performance, while confirming protection against pernicious anemia. Observational cognition benefits (PMID 41152187 Framingham) likely reflect general-health proxying rather than direct causal effect.

The dominant 2024–2026 findings: (1) oral B12 is non-inferior to IM for most patients, even in pernicious anemia (PMID 38797248, Cochrane 29543316); (2) MMA — not B12 itself — is the mortality-linked biomarker across cancer, MASLD, sarcopenia, heart failure (PMID 38702109, 38864864, 40909257, 40635893); (3) CUBN rs1801222 AA genotype roughly doubles metformin-induced deficiency risk (PMID 41537778); (4) Japan approved ultra-high-dose methylcobalamin (Rozebalamin 25 mg IM) for ALS based on JETALS Phase 3 (PMID 35532908); (5) the high-serum-B12 → cancer signal (Arendt 2013) is reverse causation, not causation — not replicated in Swedish AMORIS cohort (PMID 31020446).

The vault's distinctive position: treat B12 repletion as a deficiency question first, a performance question never. If you have documented low B12, holoTC, or elevated MMA, supplementation is high-value and safe. If your markers are mid-normal, supplementing to push levels higher has no demonstrated benefit and carries a small but real J-curve mortality signal at the population level.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence. BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal · 5–6=moderate · 3–4=weak · 1–2=speculative · 0=none Safety flags: -- No signals · MON Monitor (known AEs, manageable) · WARN Trial safety signal — see Safety section · AVOID Contraindicated for this specific indication

Prescribing

Dosing Table

Formulation Table

Cyanocobalamin vs methylcobalamin head-to-head (Cochrane/MAs + NCT05785585 ongoing): no clinically meaningful difference for deficiency correction. The Romanian HoloTC study (PMC8311243) found cyanocobalamin delivered higher active B12 than methylcobalamin in plant-based adults — directly contradicting MTHFR-community folklore that methyl is categorically superior.

Condition-Specific Protocols

Diabetic Peripheral Neuropathy (DPN)

Evidence: 4/5 (meta-analysis PMID 32716261, 38330524, 40612436)

Phase 1: Initiation (Weeks 1–2)

• Methylcobalamin 500 µg 3×/day oral OR 500 µg IM 3×/week
• Labs at baseline: B12, MMA, HbA1c, eGFR, NCV (if available)
• Goal: rule out coexisting B12 deficiency before attributing neuropathy to diabetes alone

Phase 2: Therapeutic (Weeks 3–12)

• Continue 1500 µg/d split dose oral OR 500 µg IM 2×/week
• If adding dapagliflozin (SGLT2i): combination superior per 2025 MA (PMID 40612436)
• Expected subjective: tingling reduction 4–8 weeks; objective NCV change slower (12+ weeks)

Phase 3: Maintenance (Week 12+)

• 500–1000 µg/d oral ongoing if symptomatic response
• Re-assess NCV every 12 months
• If no response by 12 weeks, re-evaluate: ensure glucose control optimized, rule out other causes (alcohol, B1 deficiency, autoimmune)

Drug Interaction Timing: Metformin is often co-prescribed — B12 status must be monitored annually (ADA 2026). Expected Outcomes: NCV improvement in small-fiber measures; modest symptom score improvements; hard endpoint (foot ulceration) benefit unproven. Stop/Reassess Criteria: No response by 12 weeks of full dose → reassess diagnosis; check MMA to verify functional repletion; consider ALC + mecobalamin combo (PMID 27180954).

Pernicious Anemia / Autoimmune Gastritis

Evidence: 5/5 (Cochrane 29543316, PMID 38797248, BSH 24942828, NICE NG239 PMID 38871397)

Phase 1: Initial Repletion (Weeks 1–4)

• UK pathway: Hydroxocobalamin 1 mg IM every other day × ~6 doses (longer if neurological involvement)
• US pathway: Cyanocobalamin 1 mg IM daily × 1 week → weekly × 4 weeks
• Modern alternative (PMID 38797248): Oral cyanocobalamin 1 mg/d achieves 88.5% repletion at 1 mo — lower barrier, patient-preferred
• Labs: B12, MMA, Hcy, CBC at baseline and 1 mo

Phase 2: Consolidation (Months 2–3)

• Taper: monthly IM OR continue 1 mg/d oral
• Symptom resolution timeline: anemia 1–2 mo, fatigue 1–3 mo, neurological (if SACD) 3–12 mo with possible residuals
• Monitor for hypokalemia during rapid repletion (rare but real; high potassium demand from accelerated erythropoiesis; genuine clinical flag)

Phase 3: Lifelong Maintenance

• 1 mg IM q1–3 months OR 1 mg/d oral
• Annual B12 + MMA + CBC + ferritin; endoscopic gastric surveillance per AGA 2021 atrophic gastritis guideline (PMID 34454714) because of gastric adenocarcinoma and carcinoid tumor risk
• Anti-parietal and anti-IF antibodies at diagnosis (NICE NG239 critique PMID 39984701 notes these are under-tested)

Stop/Reassess: Never discontinue — PA is permanent. If symptoms recur despite adequate B12, check for coexisting autoimmune conditions (thyroid, type 1 diabetes, Addison's).

ALS (Early-Stage, Japan-Only Indication)

Evidence: 4/5 (JETALS Phase 3, PMID 35532908; 52-wk extension PMID 41475066; Japan MHLW approval Sept 2024)

Eligibility: Early ALS, within defined timing from diagnosis (JETALS enrolled within 1 yr of onset). This protocol is not available in the US or EU — Rozebalamin (mecobalamin 25 mg) is approved only in Japan.

Regimen: Mecobalamin 50 mg IM twice weekly, indefinite Safety: 3.5% adverse drug reactions in 52-week extension — proteinuria, 1 supraventricular arrhythmia, 1 BUN increase, 1 HTN; 52-week survival 85.7% Outcome: Statistically significant slowing of ALSFRS-R decline vs placebo; modest magnitude but consistent

For patients outside Japan: No FDA/EMA-approved off-label equivalent; methylcobalamin 25–50 mg/week IM has been used compassionately but outside any regulatory framework. This is the single strongest high-dose indication but requires neurologist oversight.

Safety

Interactions Table

Contraindications

• Leber's hereditary optic neuropathy (LHON): Avoid cyanocobalamin — cyanide load can theoretically worsen optic-nerve damage; use hydroxocobalamin or methylcobalamin
• Cobalt hypersensitivity: Rare cobalt allergy → use non-cobalt alternatives (diagnostic workup only; clinically uncommon)
• Polycythemia vera: B12 repletion in occult PA can theoretically mask or exacerbate — specialist oversight
• Recent gastric cancer resection: Use IM, not oral (compromised intrinsic factor pathway)

Adverse Effects (ranked by frequency)

1. Injection-site reactions (IM cyano/hydroxo): erythema, mild induration — common, benign
2. Acneiform eruption (oral and IM cyanocobalamin): cystic/pustular acne on face, shoulders, chest — well-documented in both folk reports and dermatology literature; PMID 11657059 case reports; resolves on discontinuation or form switch. Methylcobalamin may be lower-risk but not zero.
3. Rosacea flare: Papulopustular rosacea can be triggered or worsened by high-dose B12 + B6 combinations (PMID 11763399 rosacea fulminans)
4. Headache, nausea, diarrhea: Low frequency; often transient
5. Anaphylaxis / hypersensitivity (injectable): Rare but documented; linked to cobalt sensitivity or the diluent; higher incidence with cyanocobalamin than hydroxocobalamin in some series
6. Hypokalemia during rapid repletion: Uncommon; severe deficiency being rapidly treated can drop K+ as marrow activates; monitor
7. "Methylation symptoms" (community-reported): Anxiety, insomnia, palpitations from methylcobalamin at high doses — mechanism unclear, likely individual variability in methionine cycle; community remedy is glycine or low-dose niacin (unvalidated but low-risk)

FAERS Signal Table

Methylcobalamin FAERS volume is ~10% of cyanocobalamin's (3,507 total), dominated by off-label and non-specific reactions. Hydroxocobalamin FAERS data is biased by Cyanokit 5g IV cyanide-antidote use (AKI 208, hyponatremia 141) — these are NOT supplement-dose signals.

Reading FAERS data: Only rows where the compound is the suspect drug are clinically meaningful. The B12 FAERS profile is dominated by multivitamin/parenteral hospital co-reporting (fatigue/nausea/headache are generic). No credible carcinogenic, neuropsychiatric, or mortality signal attributable to oral B12 supplementation.

Monitoring Table

Special Populations

Renal Impairment

Preclinical signal: PMID 41300434 shows B12 protective against ischemia-reperfusion CKD in transgenic mice — mechanistic only.

Hepatic Impairment

In MASLD, joint high-B12 + high-MMA predicts mortality (PMID 38864864) — but this is an association, not a contraindication.

Pregnancy & Lactation

• B12 is category A in pregnancy; RDA 2.6 µg/d pregnancy, 2.8 µg/d lactation
• Vegetarian/vegan pregnancy: explicit supplementation 50–250 µg/d (Spanish Pediatric Assoc PMID 31866234, GFHGNP PMID 31615715, MATCOBIND RCT PMID 41850742)
• Maternal deficiency → infant neurodevelopment risk (PMID 41461260 Nepal)
• Cochrane 2024 (PMID 38189492): insufficient evidence for pregnancy supplementation impact on maternal/infant hard outcomes — but biomarker correction is established

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Most primary B12 trials enrolled both sexes without sex-stratified analysis; the few sex-specific signals noted above are 2024–2026 findings and should be treated as exploratory.

Genetic Modifiers

Note: The MTHFR framework is the most heavily marketed pharmacogenomic modifier in the B12 space. Clinical literature does not support the "must use methylcobalamin / must avoid cyanocobalamin" doctrine for MTHFR carriers — the Romanian HoloTC study (PMC8311243) found cyanocobalamin delivered higher active B12 than methylcobalamin in vegans. McGill's Office for Science and Society has labeled commercial MTHFR testing "genetic astrology."

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Polarized across ~100,000+ community reports. Overwhelmingly positive among users with documented or suspected deficiency (r/B12_Deficiency, PAS UK); mixed-to-cautious among methylation-focused communities (Phoenix Rising, MTHFR circles); skeptically positive among vegans (evidence-oriented); commercially amplified on YouTube/med spa industry.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No dominant MLM; Dr. Mercola product line has heavy commercial promotion via content-to-product pipeline
• Influencer concentration: Ben Lynch (Seeking Health brand) commercially tied to MTHFR framework; Seeking Health sells methylcobalamin that Lynch's framework recommends — direct conflict of interest
• Astroturfing signals: Minimal for B12 itself; more visible in the MTHFR ecosystem
• Med spa industry: $15B+ wellness injection market; documented Mycobacterium abscessus infections from unregulated injectors (NBC 2024, NPR 2024)
• Homeopathic B12 patches: B12 molecule too large for transdermal passage; one documented case of life-threatening deficiency on patch reliance (ConsumerLab)
• Freddd Protocol origin: Freddd is a layperson, not a clinician; protocol doses far exceed any RCT basis

Folk vs Clinical Reality Check

Where folk is AHEAD of mainstream medicine: HoloTC and MMA as better markers than serum B12 alone (clinical literature PMC3215392, PMC7326863 supports this — up to 45% of deficient subjects missed by serum B12); pushback on too-low US serum B12 cutoff (<200 pg/mL); the "gray zone" 200–500 with symptoms deserves workup; cyanocobalamin-induced acne was folk-flagged before dermatology caught up.

Where folk is BEHIND or WRONG: MTHFR "must use methylcobalamin" doctrine is contradicted by the Romanian HoloTC data (PMC8311243); "overmethylation" as a clinically verifiable entity is not measurable without low Hcy; RLS claims are null in meta-analysis; hangover-cure claims lack any clinical data; EOD injection forever after repletion has no clinical basis; dream-vividness claims are stronger for B6 than B12.

Where folk splits from itself: Four-way form war (methyl vs cyano vs hydroxo vs adenosyl); sublingual vs IM efficacy debate (2025 MA PMC12757266 shows no significant difference); "start low go slow" vs "hit hard with EOD" camps; acne susceptibility (some blame cyano, some methyl, some both).

Deep Dive: Mechanisms & Research

Core Biochemistry

Cobalamin is a cobalt-centered corrinoid with four possible upper axial ligands: cyano (cyanocobalamin), methyl (methylcobalamin), 5'-deoxyadenosyl (adenosylcobalamin), and hydroxyl (hydroxocobalamin). The body interconverts these; only methyl- and adenosyl- are active coenzyme forms.

Two human enzymes require B12:

1. Methionine synthase (cytosolic) — uses methylcobalamin. Remethylates homocysteine → methionine → SAMe (universal methyl donor). Deficiency → elevated Hcy, impaired DNA/histone methylation.
2. Methylmalonyl-CoA mutase (mitochondrial) — uses adenosylcobalamin. Converts methylmalonyl-CoA → succinyl-CoA (TCA cycle). Deficiency → elevated MMA, impaired odd-chain fatty-acid and branched-chain amino-acid oxidation.

Absorption cascade: dietary B12 → released by pepsin + gastric acid → binds haptocorrin (saliva) → transferred to intrinsic factor (IF, parietal cells) in duodenum → IF-B12 complex absorbed at terminal ileum via cubilin-amnionless receptor (CUBN-AMN) → transferred to transcobalamin II (holoTC, the "active" fraction) → cellular uptake. Each step has potential failure points (PA = anti-IF, gastric bypass = no HCl, ileal disease = no CUBN-AMN).

Novel 2024–2026 Mechanisms

• Ttr (transthyretin) DNA methylation pathway (PMID 39029777, Biol Psychiatry 2025): B12 reduces Ttr promoter methylation in male mouse PFC, affecting stress resilience. Validated in human postmortem PFC — male-specific. First in-vivo epigenome-editing causal link between B12, DNAme, and behavior.
• Gut-microbial B12 competition via extracellular vesicles (PMID 41091075, 41846281): Bacteroides thetaiotaomicron carries BtuJ1/BtuJ2 lipoproteins with picomolar B12 affinity on EVs — effectively bacterial siderophores for cobalamin. DUF4465 domain family (1000+ members across 8 bacterial clades) all B12-binding. Rewrites understanding of microbiome-host B12 competition.
• Epigenetic aging link (PMID 40456316, NHANES 1999–2002): Hcy doubling → +1.93 years GrimAge2. Folate is the stronger one-carbon driver; B12 association modified by CKD status.
• Functional deficiency cutoff (PMID 40617951): [¹³C]-propionate oxidation breath test sets functional deficiency at serum B12 144 pmol/L — more conservative than conventional 148 pmol/L, but derived from functional assay rather than statistical distribution.
• Rhodibalamin (PMID 39012171): Noble-metal (Rh) substitution creates functional B12 cofactor mimic — structural biology advance with drug-design implications.
• Beaudry-Richard 2025 (PMID 39927551, Ann Neurol): In 231 healthy older adults ALL above current deficiency threshold, lower holoTC → delayed visual evoked potentials + slower processing speed + more WM hyperintensities; high holo-haptocorrin (inactive fraction) → elevated serum Tau. Challenges whether "normal" cutoffs are adequate in aging brain.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total registered trials (BioMCP ceiling): 250 for condition "vitamin B12"; 726 with cyanocobalamin intervention; 604 with methylcobalamin. Active recruiting: 21.

Regulatory Status (from BioMCP)

• FDA: Cyanocobalamin injectable is Rx-approved (multiple ANDAs incl. Mankind ANDA217839 AP 2024–2025, Fresenius Vibisone, Padagis nasal spray ANDA212458); oral is OTC supplement (unregulated). Methylcobalamin is not FDA-approved; sold only as dietary supplement. Hydroxocobalamin is FDA-approved as Cyanokit (5 g IV) for cyanide poisoning only — not for B12 deficiency.
• EMA: No centralized authorization; national approvals (UK, Germany, etc.) for injectable hydroxocobalamin. Cyanokit EMA-approved centrally.
• Japan (PMDA/MHLW): Methycobal (mecobalamin) approved since 1980s for peripheral neuropathy. Rozebalamin 25 mg (mecobalamin) approved September 2024 for ALS — based on JETALS Phase 3, the first ALS drug approved off a Japan-only trial in this decade.
• India (CDSCO): Methylcobalamin approved as Rx and OTC (Methycobal, Nervijen), often combined with gabapentinoids for DPN.
• Regulatory context: Methylcobalamin's US non-approval is a commercial decision, not a safety flag. The compound is well-characterized, widely used internationally for decades, and the lack of a dominant sponsor submitting to FDA reflects patent/economics rather than unresolved risk. "Not FDA-approved" ≠ "unsafe."

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: "B12 is a vitamin, so any dose is safe." Challenged by the Liu 2024 J-curve (PMID 38252787): +100 pmol/L serum B12 → +4% all-cause mortality; >600 pmol/L → HR 1.50. The signal is mostly from endogenous elevation (tissue release in occult disease), but the population-level association argues against "more is better."
• Hasty generalization: Observational cognition studies (Framingham PMID 41152187) extrapolated to "B12 supplementation improves brain aging." The Mendelian randomization study (PMID 40739033) rebuts this cleanly — MR-null for cognition and all 8 psychiatric disorders.
• Cherry-picking: MTHFR community picks Barber-style methylation-framework papers while ignoring the Romanian HoloTC vegan study (PMC8311243) that shows cyanocobalamin actually delivers higher active B12 than methylcobalamin.
• Argument from popularity: Injection-culture ("I get my monthly B12 shot for energy"), STTM optimal-5, med-spa B12 drips. Volume of enthusiasm ≠ evidence.
• Appeal to authority: Sally Pacholok + Ben Lynch as loudest voices in their respective camps — advocacy literature outpaces RCT base for many claims; commercial conflict in Lynch's case.
• False precision: "50 mg IM 2×/wk" gets copy-pasted from JETALS without the Phase-3, early-ALS-only context, onto off-label protocols that have no evidence base.

Evidence Gaps

• No head-to-head long-term RCT of methyl vs cyanocobalamin for deficiency correction with hard clinical endpoints (NCT05785585 only n=54 biomarker)
• No B12-monotherapy RCT in depression or ME/CFS meeting modern methodological standards
• No Western replication of JETALS (all ALS evidence is Japanese)
• No current USPSTF B12 screening recommendation
• No Phase 3 for Long COVID (NCT06864156 is observational only)
• Fenech "high-dose DNA damage paradox" lacks 2024–2026 primary PubMed support — should be flagged as hypothesized, not demonstrated
• Sex-specific stroke signal (KoGES PMID 39122089) needs replication outside Korea
• Genetic modifiers beyond CUBN, MTHFR, FUT2 poorly mapped (TCN2, AMN, MTR variants have weak data)

Bias Flags (Mode 4: First Principles)

• Evidence that survives scrutiny: Deficiency correction, PA treatment, DPN (modest), ALS (Japan-specific), homocysteine reduction, metformin-induced depletion prevention.
• Mechanisms with clinical translation: Methionine synthase and MMA mutase pathways. Newer Ttr-methylation pathway is mechanistic-only (no human intervention data).
• Mechanisms theoretical-only: Longevity/anti-aging, most CNS indications in replete populations, transdermal absorption.
• Dosing based on human RCTs vs animal extrapolation: Deficiency correction (human RCTs), DPN (human RCTs), ALS (JETALS Japan-only). Longevity/high-dose protocols lack human RCT basis.
• Cui bono (supplement popularity): Dominant vitamin industry, MTHFR ecosystem (Lynch/Seeking Health), med spa industry, Japanese pharma (Eisai Rozebalamin approval is a major commercial event).
• Cui bono (supplement fear): Primary-care risk-aversion, pharma competitor FUD on supplements generally (though not specific to B12).

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Energy support" claims on cyanocobalamin products — broadly legal but clinically meaningless in replete patients. "Clinical strength" labeling on sublingual products that contain pharmacologically equivalent doses to cheap oral tablets.
• Influencer economics: Ben Lynch (Seeking Health) is the archetype — his MTHFR framework sells the exact product line he recommends. Dr. Mercola operates a similar content-to-product pipeline. Dr. Berg has a branded product line. None of these are scams in the classic sense, but the conflict is direct and rarely disclosed in tandem with framework claims.
• Counter-narrative manipulation: Arendt's 2013 JNCI finding that elevated B12 correlates with cancer diagnosis within 1 year was widely cited (on both supplement-skeptic and pro-screening sides) as if it demonstrated causation. It is near-certainly reverse causation (tumor-associated haptocorrin release), and the Swedish AMORIS cohort (PMID 31020446) failed to replicate the supplementation–cancer link. Fearmongering without the reverse-causation caveat is a manipulation pattern.
• Cui bono summary: If you take B12: supplement industry, MTHFR-test industry, Japanese pharma (MeCbl), compounding pharmacies, med spas benefit. If you don't take B12 (in deficiency): primary care wins on short-term cost, insurers save on screening, but pernicious anemia patients pay in irreversible SACD. The asymmetry is striking — the cost of under-treating true deficiency is permanent neurological damage; the cost of over-treating in replete patients is ~$10/month and a small J-curve mortality signal.
• Red team highlight (most concerning angle): The mortality J-curve (PMID 38252787) plus the Beaudry-Richard 2025 holo-haptocorrin/Tau correlation (PMID 39927551) plus the inability of MR to demonstrate supplementation benefit in replete populations (PMID 40739033) collectively suggest population-wide "more is better" supplementation has NO evidence of benefit and a weak but real evidence of harm. The practical conclusion: supplement to repletion, not past it.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 — compound-intrinsic. Very high utility in documented deficiency (9/10 in that subgroup); low utility in replete population (3/10); lifelong mandatory in pernicious anemia and post-gastrectomy; high utility in chronic metformin or vegan context. Cross-domain breadth is narrow but deep where it applies (hematology, neurology, ALS-specific).
• Opportunity cost: Minimal financially ($3–8/mo for cyanocobalamin; $15–30/mo for methylcobalamin). Minimal complexity (once/day oral). Attention cost is low unless you are debugging persistent symptoms — then a workup with B12 + holoTC + MMA + folate is the right call, not more supplementation.
• Verdict: CONDITIONAL — warranted when any of the following apply:
  • Documented low B12 (<350 pg/mL) or elevated MMA (>270 nmol/L)
  • Symptomatic gray-zone B12 (200–500 pg/mL) with neurological or hematological signs
  • Chronic metformin (≥4 years or ≥1500 mg/d) — annual screening + prophylactic supplementation
  • Vegan / strict vegetarian diet — continuous supplementation, mandatory
  • Pernicious anemia / autoimmune gastritis — lifelong treatment
  • Post-gastrectomy / bariatric surgery — lifelong monitoring
  • Pregnancy in vegetarian/vegan — mandatory during pregnancy and lactation
  • Age >65 + cognitive or gait symptoms with hyperhomocysteinemia — trial with folate + ω-3 co-supplementation
  • Established diabetic peripheral neuropathy — mecobalamin-containing regimen
  • Chronic N₂O exposure — functional deficiency protocol
  • Levodopa therapy in Parkinson's — screen B12 to prevent Hcy acceleration
• NOT warranted for: generic "energy" supplementation in replete adults, cognitive enhancement in healthy adults, "longevity" high-dose protocols, hair-loss or hair-color reversal without deficiency, depression/mood optimization in replete adults, hangover prevention, weight loss, or dermatological uses.

Bottom Line

Vitamin B12 is the archetype of a "sometimes essential, mostly ignorable" supplement. It is mandatory for a well-defined list of populations (vegans, PA, chronic metformin, post-gastrectomy, pregnancy in restrictive diets) where the cost of non-supplementation is irreversible neurological damage; it is prudent for an expanded list of at-risk groups where the cost of under-supplementation is fatigue, neuropathy, or cognitive decline that could have been prevented; and it is essentially useless for the majority of healthy, non-deficient, omnivorous adults who dominate supplement marketing. The most important clinical update is ADA 2026's explicit annual-screening recommendation for chronic metformin users — this turns an ignored side effect into an actively managed one. The most important research update is the Japanese Rozebalamin approval, which validates ultra-high-dose mecobalamin as an ALS-modifying drug in one country but leaves the US/EU behind. The most important safety update is that MMA — not B12 itself — is the mortality-predicting biomarker, which reframes "high B12" fears as "high MMA worries." The most important honesty update is that the MR-null finding for cognition and psychiatric outcomes in replete populations should significantly deflate the "B12 for mental clarity" narrative.

Practical Notes

Brands & Product Selection

Oral cyanocobalamin (default):

• Jarrow Formulas Methyl B-12 (~$9 for 100 × 1000 µg lozenges) — long history, NSF/GMP facility
• NOW Foods B-12 1000 µg — reliable, budget
• Seeking Health Methyl-B12 / Adeno-B12 — expensive; Ben Lynch brand; no demonstrated advantage but acceptable quality
• Garden of Life mykind — methylcobalamin, non-synthetic marketing; acceptable
• Thorne Methylcobalamin — pharmaceutical-grade; good for those prioritizing third-party testing

Injectable (prescription):

• UK NHS: hydroxocobalamin ampoules (most common)
• US Rx: cyanocobalamin 1 mg/mL (Mankind, Fresenius Vibisone, West-Ward)
• Japan: Methycobal 500 µg ampoules (Rx); Rozebalamin 25 mg (specialist, ALS only)

Quality markers to check: Third-party testing (NSF, USP, or Labdoor); cGMP manufacturing; transparent COA (certificate of analysis); dose matches label (Consumer Lab has repeatedly found underdose and overdose variance in supplement channels — ConsumerLab.com B12 reports 2022–2024).

Red flags: "Proprietary energy blend" obscuring B12 dose; transdermal patches (don't work); sprays with unverified bioavailability claims; B12 + stimulant combos (red-bull-style products); unregistered med-spa injectors.

Storage & Handling

• Oral tablets/lozenges: room temperature, dry, dark. Shelf life 2–3 years.
• Injectable cyanocobalamin: 15–30°C, protected from light. Do not freeze.
• Hydroxocobalamin (Cyanokit): 15–25°C; reconstituted solution stable 6 hours.
• Liquid/sublingual formulations: some require refrigeration post-opening — check label.
• Methylcobalamin is light-sensitive — keep sublingual tabs in opaque containers.

Palatability & Compliance

• Oral tablets are small, no taste.
• Sublingual lozenges are typically sweet (mannitol, fructose) — hold 45+ seconds under tongue; actual mechanism of "sublingual advantage" is unproven, but the slow dissolve increases gastric exposure time which may help in low-acid patients.
• Self-injection (UK PAS community): 25G × 5/8" SC into thigh; ampoules from EU pharmacies; sterile technique essential.
• Common compliance failure: stopping because "I feel fine now" — in PA this leads to slow-motion SACD over months to years.

Exercise & Circadian Timing

• AM dosing preferred — community reports of insomnia with PM dosing (especially methylcobalamin). Clinical data on circadian effect thin; Chronobiology International 2026 review (PMID 41992896) notes plausible but indirect evidence.
• No meaningful pre/post-workout role; B12 is not an acute ergogenic.
• For IM injections: morning is practical because "wake-up symptoms" (if they occur) land during the day rather than disrupting sleep.

Reference Ranges (Expected Biomarker Changes)

Cost

• Oral cyanocobalamin 1000 µg/d: ~$3–8/month
• Oral methylcobalamin 1000 µg/d: ~$8–20/month
• Sublingual high-dose (5000 µg) methylcobalamin: ~$15–30/month
• IM cyanocobalamin 1 mg monthly (Rx US): ~$5–15/month plus clinic fees
• IM hydroxocobalamin 1 mg EOD self-administered (UK): ~€0.50–1.50/ampoule (EU pharmacy sourced)
• Rozebalamin 25 mg IM 2×/wk (Japan only): Rx cost, specialist neurologist administered

Cyanocobalamin is 2–5× cheaper than methylcobalamin with no demonstrated clinical inferiority for the typical reader. For documented methylation-sensitive individuals or those with MTRR variants, methylcobalamin may be worth the premium; for everyone else, cyanocobalamin is the cost-effective default.

What We Don't Know

• Whether methyl- vs cyanocobalamin matters clinically for hard endpoints beyond biomarker correction (NCT05785585 will help; n=54 underpowered for hard outcomes).
• Whether the JETALS mecobalamin 50 mg ALS protocol will replicate in non-Japanese populations (no Western Phase 3 exists or is planned at 2026).
• Whether the Fenech "high-dose DNA-damage paradox" is a real clinical concern or legacy hypothesis — 2024–2026 primary literature does not validate the framing.
• Whether the holo-haptocorrin / Tau correlation (PMID 39927551) reflects causation or a shared aging marker.
• Whether CUBN rs1801222 AA genotype warrants population-wide screening in metformin users or should remain a research tool — no cost-effectiveness analysis exists yet.
• Whether chronic low-level N₂O exposure (dental, recreational "minor use") accumulates to functional deficiency over decades.
• Whether the sex-specific stroke signal at high B12 in males (PMID 39122089) replicates outside the Korean KoGES cohort.
• Whether vegan functional deficiency (PMID 39373282) is clinically meaningful if MMA remains normal — the biomarker panel may overdiagnose.
• Whether "overmethylation" symptoms on methylcobalamin reflect a real phenomenon or a placebo-nocebo community artifact.

References

Meta-analyses & Cochrane Reviews

• PMID 29543316 — Wang 2018 Cochrane: oral vs IM B12. Low-certainty evidence oral is as effective at 3 mo
• PMID 38189492 — Finkelstein 2024 Cochrane: B12 supplementation in pregnancy; insufficient hard-outcome evidence
• PMID 38231320 — Abdelwahab 2024: Network MA of B12 routes; oral and IM equally effective
• PMID 38252787 — Liu 2024 Arch Gerontol Geriatr: dose-response mortality MA, 22 cohorts, 92,346 individuals. +100 pmol/L → +4% mortality; >600 pmol/L HR 1.50
• PMID 32716261 — Sawangjit 2020: mecobalamin peripheral neuropathy MA; modest efficacy
• PMID 38330524 — Ran 2024: disease-modifying therapies for DPN; mecobalamin favored
• PMID 40612436 — 2025: Dapagliflozin + methylcobalamin in T2DM DPN MA
• PMID 34432056 — Wang 2022: B-vit and cognitive decline; no benefit in unselected older adults
• PMID 33809274 — Markun 2021 Nutrients: B12 on cognition/depression/fatigue; no consistent benefit in non-deficient
• PMID 38700503 — Lee 2024: B12 + folate in Alzheimer's; no significant MMSE/ADAS-cog improvement
• PMID 38953947 — Luo 2024: B-vit and bone health; null + trial sequential confirms futility
• PMID 39438181 — Cadd 2024: hydroxocobalamin vs methylene blue post-CPB vasoplegia
• PMID 37147207 — Brokmeier 2023: hydroxocobalamin vs methylene blue vasoplegic shock; methylene blue favored
• PMID 39373282 — Niklewicz 2024 Nutr Bull: functional B12 in vegans; SMD -0.72 serum B12; +0.57 tHcy
• PMID 40823471 — 2025 Cureus: PPI and B12 status MA — null for total B12 and tHcy (n=3859)
• PMID 38291560 — 2024: Vitamins A–E for stroke risk; network MA mixed
• PMID 37850302 — 2024: B-vitamins for CVD; modest Hcy reduction, null hard endpoints
• PMID 38824900 — 2024: Folic acid for stroke prevention (B12 co-intervention); 21 RCTs
• PMID 41362547 — Behringer 2025: natural vs synthetic B12 forms; hydroxo-/methylcobalamin preferred bioactivation; cyano adequate

Landmark RCTs

• PMID 35532908 — JETALS 2022 JAMA Neurol: Mecobalamin 50 mg 2×/wk in early ALS; primary endpoint met
• PMID 41475066 — JETALS 52-wk extension 2026: 85.7% survival; 3.5% ADRs
• PMID 38797248 — 2024 AJCN: Oral cyanocobalamin 1000 µg/d in PA; 88.5% repletion at 1 mo
• PMID 9694707 — Kuzminski 1998 Blood: Oral 2 mg/d vs IM monthly; oral superior on serum B12
• PMID 26757190 — Oulhaj 2016: VITACOG B-vit × omega-3 interaction for cognitive benefit
• PMID 25877495 — Jernerén 2015 AJCN: VITACOG brain atrophy reduction; requires adequate ω-3
• PMID 27180954 — Li 2016: ALC + mecobalamin for DPN; combination superior
• PMID 39927551 — Beaudry-Richard 2025 Ann Neurol: Low holoTC → delayed VEP + slower processing + WM hyperintensities in above-threshold older adults
• PMID 41548600 — 2026 J Nutr: Oral 1000 vs 2000 µg in DPN + low B12
• PMID 40055025 — 2025 J Cardiothorac Vasc Anesth: Hydroxocobalamin for post-CPB vasoplegia prevention
• PMID 36045399 — 2022: B12 for fibromyalgia; FIQR improvement

Mechanism & Biomarker Studies

• PMID 39029777 — Biol Psychiatry 2025: B12 → Ttr promoter demethylation → stress resilience (male-specific)
• PMID 41091075 — Biochem J 2025: Bacteroides EVs + BtuJ1/BtuJ2 B12-binding proteins
• PMID 41846281 — FEBS Open Bio 2026: DUF4465 domain family widespread B12-binding
• PMID 40456316 — 2025 AJCN: Epigenetic aging + one-carbon metabolism; Hcy doubling → +1.93 y GrimAge2
• PMID 39012171 — Biochemistry 2024: Rhodibalamin cofactor mimic
• PMID 40617951 — 2025 Sci Rep: ¹³C-propionate breath test functional cutoff 144 pmol/L
• PMID 41152187 — Alzheimers Dement 2025: Framingham B12 + cognitive decline; robust when folate adequate
• PMID 40739033 — Commun Med 2025: Mendelian randomization B12 and psychiatric outcomes; null except pernicious anemia (OR 0.24)
• PMID 40717068 — BMC Med 2025: One-carbon metabolism × ApoE × cognition interaction

Safety & Epidemiology

• PMID 39122089 — J Nutr 2024: KoGES excessive B12 + stroke in males (HR 1.81)
• PMID 38702109 — AJCN 2024: MMA (not B12) predicts mortality in cancer survivors; joint high B12 + high MMA HR 2.06
• PMID 38864864 — Eur J Nutr 2024: MASLD + high MMA + high B12; all-cause HR 1.82, CVD HR 2.28
• PMID 40909257 — Food Sci Nutr 2025: NHANES sarcopenia; MMA → muscle loss + mortality
• PMID 40635893 — Front Nutr 2025: B12/MMA and HF mortality
• PMID 41626614 — Front Nutr 2026: Elevated MMA predicts mortality in hyperlipidemic adults
• PMID 41396044 — Clin Toxicol 2026: 22-year US poison center N₂O data
• PMID 40546460 — 2025: N₂O thromboembolism association
• PMID 40356911 — 2025: SACD from recreational N₂O comparison
• PMID 24249744 — Arendt 2013 JNCI: Elevated B12 and cancer (reverse causation)
• PMID 31020446 — Swedish AMORIS: Cancer link not replicated
• PMID 38262891 — 2024 Arch Gerontol Geriatr: Endogenous vs exogenous B12 elevation; clinical implications

Pharmacogenomics

• PMID 41537778 — Diabetologia 2026: CUBN rs1801222 metformin + B12 deficiency pharmacogenomic
• PMID 39196375 — Ann Hematol 2024: MTHFR polymorphisms + B12 deficiency
• PMID 38892484 — Nutrients 2024: Methylfolate + P5P + methylcobalamin in MTHFR/MTR/MTRR carriers
• PMID 41031637 — Database 2025: CobVar B12-associated genomic variants database
• PMID 36969181 — Front Immunol 2023: MR folate/B12 and autoimmune disease risk

Guidelines & Regulatory

• PMID 38871397 — BMJ 2024: NICE NG239 B12 deficiency in over-16s summary
• PMID 38713783 — 2024: NICE NG239 full guideline
• PMID 24942828 — 2014: BSH cobalamin and folate disorders
• PMID 34454714 — 2021: AGA Clinical Practice Update atrophic gastritis
• PMID 39984701 — 2025 EJCN: NICE NG239 critique on pernicious anemia recognition
• PMID 40961307 — 2025 Am Fam Physician: AAFP common-questions review; B12 >1000 pg/mL persistent → malignancy/CV surveillance
• PMID 31866234 — 2020: Spanish Pediatric Assoc vegetarian diets infants (mandatory B12)
• PMID 31615715 — 2019: GFHGNP French vegan diet children (mandatory B12)
• PMID 33212246 — 2021: SOGC No. 410 fetal neural tube defects (B12 preconception)

Pregnancy

• PMID 41850742 — BMJ Paediatr Open 2026: MATCOBIND RCT maternal B12 + infant neurodev
• PMID 41461260 — J Nutr 2026: B12 in pregnancy and infant motor performance (Nepal)
• PMID 38189492 — Cochrane pregnancy 2024

Japan-specific ALS / DPN evidence

• PMID 39083229 — Curr Opin Neurol 2024: Kaji JETALS review
• PMID 31722312 — JETALS protocol paper
• PMID 30578206 — JETALS design paper

Diagnostics

• PMID 39367523 — Ann Clin Biochem 2025: Biomarker interpretation review
• PMID 38987873 — 2024 Nexo & Parkner: B12-related biomarkers
• PMID 38987879 — 2024 Wolffenbuttel/McCaddon diagnosis + treatment

Cross-domain (cardiovascular, thyroid, etc.)

• PMID 41923733 — Rev Cardiovasc Med 2026: Sex-specific HRV + B12/folate/iron
• PMID 39266685 — J Hum Hypertens 2024: Folate/B12 deficiency + childhood HTN
• PMID 39548360 — BMC Cardiovasc Disord 2024: Hcy + CVD mortality NHANES
• PMID 40283381 — J Clin Med 2025: Food cobalamin malabsorption review
• PMID 38474790 — Nutrients 2024: Autoimmune gastritis framework

Renal / Miscellaneous

• PMID 41300434 — Antioxidants 2025: B12 in ischemia-reperfusion CKD (preclinical)
• PMID 37167532 — Nutr Rev 2024: Metformin impact on cobalamin status (Fituri)
• PMID 36401952 — RLS association review (weak)
• PMID 11763399 — Rosacea fulminans from B6/B12 (legacy case)
• PMID 11657059 — B12-induced acneiform eruption case reports
• PMID 10256894 — Acneiform eruption from B12 (legacy)
• PMID 39047712 — 2024 Psychopathology: Hallucinations + B12 deficiency systematic review (50 cases)
• PMID 38421889 — 2024 Br J Community Nurs: B12 and mental-health outcomes review
• PMID 41128447 — Curr Opin Clin Nutr 2026: B12 + geriatric syndromes review
• PMID 39940277 — Nutrients 2025: Dispersible D 2500 IU + B12 1000 µg multicenter RCT
• PMID 41992896 — Chronobiol Int 2026: Nutritional sleep modulators narrative review